Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluate the Safety and Efficacy of Optimized Antiplatelet Therapy in Patients With Coronary Heart Disease After Implantation of NeoVas™ Bioabsorbable Coronary Artery Rapamycin-eluting Stent System.

NCT04995159 is registered in ClinicalTrials.gov with Lepu Medical Technology (Beijing) Co., Ltd. as lead sponsor.

NCT NCT04995159
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04995159 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluate the Safety and Efficacy of Optimized Antiplatelet Therapy in Patients With Coronary Heart Disease After Implantation of NeoVas™ Bioabsorbable Coronary Artery Rapamycin-eluting Stent System.
Lead sponsor
Lepu Medical Technology (Beijing) Co., Ltd.
Phase
Not applicable
Overall status
Not yet recruiting
Start date
September 30, 2021
Completion date
January 31, 2028
Enrollment
2,150 (estimated)
Sites
114

Conditions

As the registry lists them; a condition with its own page is linked.

coronary heart disease